Seer (NASDAQ:SEER) is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow. Researchers can simultaneously capture and quantify thousands of proteins from small volumes of blood, plasma or other biospecimens, providing insights into disease pathways, target validation and therapeutic response that were previously inaccessible through traditional proteomic approaches.
Founded in 2018 and headquartered in Redwood City, California, Seer has rapidly expanded its reach to serve pharmaceutical and biotechnology companies, academic research centers and clinical laboratories worldwide. Since going public on the Nasdaq in mid-2021, the company has continued to invest in R&D to enhance its product capabilities, drive assay reproducibility and broaden applications across immuno-oncology, neurology, cardiovascular disease and other therapeutic areas.
Guided by a management team with deep expertise in proteomics, genomics, instrumentation and data analytics, Seer aims to democratize access to comprehensive protein measurement at scale. Its ongoing collaborations with leading life sciences organizations underscore the growing demand for proteomic insights in advancing drug development, enabling personalized diagnostics and unlocking new understandings of human health and disease.
